Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Threshold Presses On In Two Phase III Cancer Trials As Competitors Wilt

Executive Summary

Threshold and partner Merck Serono are benefiting from recent high-profile failures in sarcoma and pancreatic cancer. Armed with $100 million in payments since signing with Merck in February 2012, Threshold needs to rise above stiff odds and what some view as equivocal Phase II pancreatic cancer results.

You may also be interested in...

On The Threshold Of The Tumor Microenvironment

Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.

The Art Of Cutting Costs Without Jeopardizing Growth: An Interview With Merck Serono's Belén Garijo

Having emerged from a radical restructuring with new senior management, a revamped portfolio and a strategic ambition to morph into an oncology powerhouse on the back of its emerging markets business, CEO Belén Garijo says Merck Serono is poised to enter its growth phase.

EMA Fells Two Orphan Drugs, Delays Teva’s Nerventra

The CHMP rejects AB Science’s Masiviera for pancreatic cancer, PTC Therapeutics’ Translarna for Duchenne muscular dystrophy and Teva’s Nerventra for MS.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts